Guidelines on Hepatitis B and C Testing PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Guidelines on Hepatitis B and C Testing PDF full book. Access full book title Guidelines on Hepatitis B and C Testing by World Health Organization. Download full books in PDF and EPUB format.
Author: World Health Organization Publisher: World Health Organization ISBN: 9789241549981 Category : Medical Languages : en Pages : 0
Book Description
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.
Author: World Health Organization Publisher: World Health Organization ISBN: 9789241549981 Category : Medical Languages : en Pages : 0
Book Description
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.
Author: Publisher: ISBN: 9789241550345 Category : Languages : en Pages : 84
Book Description
These guidelines aim to provide evidence-based recommendations on the care and treatment of persons diagnosed with chronic HCV (Hepatitis C Virus) infection. They update the care and treatment section of the WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection issued in April 2016. The 2017 Guidelines on hepatitis B and C testing update the screening section.
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309438020 Category : Medical Languages : en Pages : 187
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309153689 Category : Medical Languages : en Pages : 252
Book Description
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.
Author: World Health Organization Publisher: World Health Organization ISBN: 9241549610 Category : Medical Languages : en Pages : 140
Book Description
The field of HCV therapeutics continues to evolve rapidly and since the World Health Organization (WHO) issued its first Guidelines for the screening care and treatment of persons with hepatitis C infection in 2014 several new medicines have been approved by at least one stringent regulatory authority. These medicines called direct-acting antivirals (DAAs) are transforming the treatment of HCV enabling regimens that can be administered orally are of shorter duration (as short as eight weeks) result in cure rates higher than 90% and are associated with fewer serious adverse events than the previous interfere on containing regimens. WHO is updating its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines. The objectives of these WHO guidelines are to provide updated evidence-based recommendations for the treatment of persons with hepatitis C infection using where possible all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient?s HCV genotype and clinical history and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014. The key audience for these guidelines are policy-makers in low- and middle-income countries who formulate country-specific treatment guidelines and who plan infectious disease treatment programmes and services in addition to those people responsible for delivering treatment. The guidelines are appropriate for all countries including high-income countries.
Author: World Health Organization Publisher: World Health Organization ISBN: 924154905X Category : Medical Languages : en Pages : 166
Book Description
These are the first World Health Organization (WHO) guidelines for the prevention care and treatment of persons living with CHB infection and complement similar recent published guidance by WHO on the prevention care and treatment of infection due to the hepatitis C virus (HCV). In contrast to several recent international guidelines on the management of CHB infection from the United States Europe Asia-Pacific and the United Kingdom (UK) the primary audience for these WHO guidelines is country programme managers in all settings but particularly in LMICs to help plan the development and scale up of hepatitis B prevention care and treatment. These guidelines are also intended for health-care providers who care for persons with CHB in these settings. The recommendations are structured along the continuum of care for persons with CHBa from initial assessment of stage of disease and eligibility for treatment to initiation of first-line antiviral therapy and monitoring for disease progression toxicity and HCC and switch to second-line drugs in persons with treatment failure. They are intended for use across age groups and adult populations. The recommendations in these guidelines promote the use of simple non-invasive diagnostic tests to assess the stage of liver disease and eligibility for treatment; prioritize treatment for those with most advanced liver disease and at greatest risk of mortality; and recommend the preferred use of nucleos(t)ide analogues with a high barrier to drug resistance (tenofovir and entecavir and entecavir in children aged 2–11 years) for first- and second-line treatment. These guidelines also recommend lifelong treatment in those with cirrhosis; and regular monitoring for disease progression toxicity of drugs and early detection of HCC. An additional chapter highlights management considerations for specific populations including those coinfected with HIV HCV and hepatitis D virus (HDV); children and adolescents; and pregnant women.
Author: Mitchell L. Shiffman Publisher: Springer Science & Business Media ISBN: 1461411920 Category : Medical Languages : en Pages : 333
Book Description
Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV.
Author: Angelos Hatzakis Publisher: Springer Nature ISBN: 3030677621 Category : Medical Languages : en Pages : 219
Book Description
This volume provides the reader with a detailed overview of the current state-of-the art approach of Hepatitis C management. It reviews the course of action in handling of chronic Hepatitis C patients with various HCV genotypes and treats special cases such as acute hepatitis, transplant and renal patients as well as people who inject drugs. The two volume work on Hepatitis C introduces to the topic by reviewing virology, diagnosis, epidemiology, prevention, management and elimination of HCV. The book provides a valuable source at full length for researchers and clinicians working on Hepatitis C.
Author: Nan Kong Publisher: John Wiley & Sons ISBN: 1118960130 Category : Business & Economics Languages : en Pages : 430
Book Description
A systematic review of the most current decision models and techniques for disease prevention and treatment Decision Analytics and Optimization in Disease Prevention and Treatment offers a comprehensive resource of the most current decision models and techniques for disease prevention and treatment. With contributions from leading experts in the field, this important resource presents information on the optimization of chronic disease prevention, infectious disease control and prevention, and disease treatment and treatment technology. Designed to be accessible, in each chapter the text presents one decision problem with the related methodology to showcase the vast applicability of operations research tools and techniques in advancing medical decision making. This vital resource features the most recent and effective approaches to the quickly growing field of healthcare decision analytics, which involves cost-effectiveness analysis, stochastic modeling, and computer simulation. Throughout the book, the contributors discuss clinical applications of modeling and optimization techniques to assist medical decision making within complex environments. Accessible and authoritative, Decision Analytics and Optimization in Disease Prevention and Treatment: Presents summaries of the state-of-the-art research that has successfully utilized both decision analytics and optimization tools within healthcare operations research Highlights the optimization of chronic disease prevention, infectious disease control and prevention, and disease treatment and treatment technology Includes contributions by well-known experts from operations researchers to clinical researchers, and from data scientists to public health administrators Offers clarification on common misunderstandings and misnomers while shedding light on new approaches in this growing area Designed for use by academics, practitioners, and researchers, Decision Analytics and Optimization in Disease Prevention and Treatment offers a comprehensive resource for accessing the power of decision analytics and optimization tools within healthcare operations research.
Author: World Health Organization
Author: World Health Organization
Author: 
Author: National Academies of Sciences, Engineering, and Medicine
Author: Institute of Medicine
Author: World Health Organization
Author: World Health Organization
Author: World Health Organization
Author: Mitchell L. Shiffman
Author: Angelos Hatzakis
Author: Nan Kong